Acerta Pharma, an affiliate of AstraZeneca, is pushing the boundaries of science to redefine care in haematology. By leveraging our scientific platforms to develop and test novel investigational agents designed to directly kill cancer cells or harness the immune system to recognise and eliminate cancer. By addressing blood cancers with high unmet needs, we are advancing our pipeline to enrich first-in-class agents and to deliver best-in-class medicines.
.png)
Our Science
Drug Discovery
Acerta Pharma, in close collaboration with AstraZeneca, takes an innovative approach to discover, develop and deliver targeted novel transformational medicines for patients with hematological malignancies.
Innovative Clinical Studies
Working together Acerta and AstraZeneca are focused on Innovative Clinical Strategies to enable us to combine our extensive oncology portfolio of cancer therapies.
Resistance Biology
The AstraZeneca and Acerta research organization has deep expertise in innovative drug profiling technologies. Our multi-omic platforms enables the characterization of underlying complex biology in various cell subsets.
Research & Development in the Netherlands
At our recently expanded site at Oss in the Netherlands, we have core capabilities in target identification, target validation, lead generation and compound optimization. Working together, Acerta and AstraZeneca are focused on Innovative Clinical Strategies to enable us to combine our extensive oncology of cancer therapies. The Oss R&D center is based in the heart of the Pivot Park Biotechnology Campus and has established relationships with both academic and commercial partners in Europe.